Compare Bumble Inc (BMBL) vs Boston Scientific Corporation (BSX) Price & Performance

BMBL trades at $2.73, down 3.53% on the day, with a bearish technical outlook. The company reported a Q2 2026 earnings miss and negative net income margin of -57.96%, though revenue of $965.66M in 2025 shows scale. Recent news highlights a major shift in its women-first messaging policy to boost engagement amid slowing growth and exploration of a potential sale.

The outlook is challenged by persistent losses and declining paying users, but a low P/S of 0.38 offers valuation appeal. Risks include execution of product changes and intense competition. Analysts are mostly neutral with a $3.62 price target, suggesting cautious optimism if turnaround efforts succeed.

Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.

BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.